Jun 7 2010
Managing Myeloma is pleased to announce the launch of the Myeloma Treatment Resource® (MTR®) at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago. The MTR, developed by the Managing Myeloma multidisciplinary scientific advisors, is a compilation of convenient, unique tools and resources essential for practitioners treating patients with multiple myeloma.
The first tool, the Patient Regimen Calendar, was by far the most anticipated tool by the advisors. With this application, a practitioner chooses a patient's regimens and cycles from a drop-down menu and the tool will fill in the drug name on the specific date to be taken for the length of the cycle. The practitioner can print the calendar out, creating a clear and concise patient takeaway. This tool is invaluable for the patient and practitioner as it clearly and accurately states what medication to take and when, giving the patient confidence in their at-home care by reducing confusion and ultimately, saving time for office staff responsible for answering patient queries and pulling patient charts.
The second tool is the Compendium of Drug Regimens. The compendium contains all of the current regimens and future agents currently in the practitioner's arsenal. The tool lists the regimen; recommended dose/schedule; FDA approval and NCCN recommendation; standard of care for 2010; response rate and duration; survival; and common AEs and/or grade 3/4 toxicities. A complete reference at the practitioner's fingertips, it is frequently updated to meet the needs of the ever-changing multiple myeloma environment. "There is nothing else currently offered to practitioners that is as comprehensive or as easy to retrieve information from as this tool. A must-have for practitioners," says Gene Tombler, PhD, contributor and editor of the compendium.
The third tool launched, the Diagnosis, Staging, Prognosis, and Response Guide, is designed to be an invaluable reference resource for practitioners. The tool is conveniently separated into specific topic areas for quick information retrieval and covers the most common clinical features of multiple myeloma at presentation; recommended laboratory tests for diagnosis, prognosis and risk-stratification, including the roles of the serum free light chain assay, definitions of myeloma and related monoclonal gammopathies; a basic diagnostic algorithm; International Staging System and the International Myeloma Working Group Uniform Response Criteria among other features. All of these tools and more may be accessed by logging onto www.ManagingMyeloma.com.
Study addresses knowledge gap of clinical features and outcomes of Black patients with melanoma